抗体偶联药物戈沙妥组单抗在三阴性乳腺癌中的研究进展

Research progress of the antibody-drug conjugate sacituzumab govitecan-hziy in triple-negative breast cancer

三阴性乳腺癌是雌激素受体、孕激素受体和人表皮生长因子受体2三者均为阴性表达的侵袭性乳腺癌亚型,临床尚缺乏有效的治疗手段。戈沙妥组单抗是美国食品药品管理局批准的首款治疗三阴性乳腺癌的抗体偶联药物,也是全球首个获批靶向人滋养层细胞表面抗原2的抗体偶联药物,为转移性三阴性乳腺癌患者提供了新的治疗选择。临床研究表明,戈沙妥组单抗在转移性三阴性乳腺癌患者中具有较好的抗癌活性,且安全性良好。本文就戈沙妥组单抗在三阴性乳腺癌中的研究进展进行介绍。

Triple-negative breast cancer(TNBC) is an aggressive subtype of breast cancer defined with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Current therapeutic options for TNBC are limited. As the first antibody-drug conjugate approved by the U.S. Food and Drug Administration for the treatment of TNBC,sacituzumab govitecan-hziy is also a first-in-class ADC approved to target trophoblast cell-surface antigen 2,which provides a new treatment option for patients with metastatic TNBC. Clinical studies have shown that sacituzumab govitecan-hziy has good anticancer activity and good safety in patients with metastatic TNBC. Here, the research progress of sacituzumab govitecan-hziy in TNBC is introduced.